These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 20142523)

  • 1. A randomized, placebo-controlled trial of latrepirdine in Huntington disease.
    Kieburtz K; McDermott MP; Voss TS; Corey-Bloom J; Deuel LM; Dorsey ER; Factor S; Geschwind MD; Hodgeman K; Kayson E; Noonberg S; Pourfar M; Rabinowitz K; Ravina B; Sanchez-Ramos J; Seely L; Walker F; Feigin A;
    Arch Neurol; 2010 Feb; 67(2):154-60. PubMed ID: 20142523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, double-blind, placebo-controlled study of latrepirdine in patients with mild to moderate Huntington disease.
    HORIZON Investigators of the Huntington Study Group and European Huntington's Disease Network
    JAMA Neurol; 2013 Jan; 70(1):25-33. PubMed ID: 23108692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Latrepirdine for Alzheimer's disease.
    Chau S; Herrmann N; Ruthirakuhan MT; Chen JJ; Lanctôt KL
    Cochrane Database Syst Rev; 2015 Apr; 2015(4):CD009524. PubMed ID: 25897825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington's disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial.
    Furr Stimming E; Claassen DO; Kayson E; Goldstein J; Mehanna R; Zhang H; Liang GS; Haubenberger D;
    Lancet Neurol; 2023 Jun; 22(6):494-504. PubMed ID: 37210099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial.
    De Jesus Moreno Moreno M
    Clin Ther; 2003 Jan; 25(1):178-93. PubMed ID: 12637119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence for the efficacy of latrepirdine (Dimebon) treatment for improvement of cognitive function: a meta-analysis.
    Cano-Cuenca N; Solís-García del Pozo JE; Jordán J
    J Alzheimers Dis; 2014; 38(1):155-64. PubMed ID: 23948924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study.
    Reilmann R; McGarry A; Grachev ID; Savola JM; Borowsky B; Eyal E; Gross N; Langbehn D; Schubert R; Wickenberg AT; Papapetropoulos S; Hayden M; Squitieri F; Kieburtz K; Landwehrmeyer GB; ;
    Lancet Neurol; 2019 Feb; 18(2):165-176. PubMed ID: 30563778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, tolerability, and efficacy of PBT2 in Huntington's disease: a phase 2, randomised, double-blind, placebo-controlled trial.
    Huntington Study Group Reach2HD Investigators
    Lancet Neurol; 2015 Jan; 14(1):39-47. PubMed ID: 25467848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington's disease.
    Huntington Study Group HART Investigators
    Mov Disord; 2013 Sep; 28(10):1407-15. PubMed ID: 23450660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal dosing of galantamine in patients with mild or moderate Alzheimer's disease: post Hoc analysis of a randomized, double-blind, placebo-controlled trial.
    Aronson S; Van Baelen B; Kavanagh S; Schwalen S
    Drugs Aging; 2009; 26(3):231-9. PubMed ID: 19358618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial.
    de Yebenes JG; Landwehrmeyer B; Squitieri F; Reilmann R; Rosser A; Barker RA; Saft C; Magnet MK; Sword A; Rembratt A; Tedroff J;
    Lancet Neurol; 2011 Dec; 10(12):1049-57. PubMed ID: 22071279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial.
    Farlow M; Potkin S; Koumaras B; Veach J; Mirski D
    Arch Neurol; 2003 Jun; 60(6):843-8. PubMed ID: 12810489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial.
    Puri BK; Leavitt BR; Hayden MR; Ross CA; Rosenblatt A; Greenamyre JT; Hersch S; Vaddadi KS; Sword A; Horrobin DF; Manku M; Murck H
    Neurology; 2005 Jul; 65(2):286-92. PubMed ID: 16043801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group.
    Rogers SL; Doody RS; Mohs RC; Friedhoff LT
    Arch Intern Med; 1998 May; 158(9):1021-31. PubMed ID: 9588436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of a loading-dose regimen versus a no-loading-dose regimen of metrifonate in the symptomatic treatment of Alzheimer's disease: a randomized, double-masked, placebo-controlled trial. Metrifonate Study Group.
    Jann MW; Cyrus PA; Eisner LS; Margolin DI; Griffin T; Gulanski B
    Clin Ther; 1999 Jan; 21(1):88-102. PubMed ID: 10090427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bupropion for the treatment of apathy in Huntington's disease: A multicenter, randomised, double-blind, placebo-controlled, prospective crossover trial.
    Gelderblom H; Wüstenberg T; McLean T; Mütze L; Fischer W; Saft C; Hoffmann R; Süssmuth S; Schlattmann P; van Duijn E; Landwehrmeyer B; Priller J
    PLoS One; 2017; 12(3):e0173872. PubMed ID: 28323838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300).
    Orgogozo JM; Rigaud AS; Stöffler A; Möbius HJ; Forette F
    Stroke; 2002 Jul; 33(7):1834-9. PubMed ID: 12105362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomised, placebo-controlled, double blind study of treatment of Huntington's disease with unsaturated fatty acids.
    Vaddadi KS; Soosai E; Chiu E; Dingjan P
    Neuroreport; 2002 Jan; 13(1):29-33. PubMed ID: 11924889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ABT-126 monotherapy in mild-to-moderate Alzheimer's dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension.
    Gault LM; Lenz RA; Ritchie CW; Meier A; Othman AA; Tang Q; Berry S; Pritchett Y; Robieson WZ
    Alzheimers Res Ther; 2016 Oct; 8(1):44. PubMed ID: 27756421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Latrepirdine: molecular mechanisms underlying potential therapeutic roles in Alzheimer's and other neurodegenerative diseases.
    Bharadwaj PR; Bates KA; Porter T; Teimouri E; Perry G; Steele JW; Gandy S; Groth D; Martins RN; Verdile G
    Transl Psychiatry; 2013 Dec; 3(12):e332. PubMed ID: 24301650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.